Jennifer A. Woyach
Advanced in Waldenstrom Macroglobulinemia

Dr. Jennifer A. Woyach

Hematology | Oncology
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
17 Years of Experience
Advanced in Waldenstrom Macroglobulinemia
Osu Internal Medicine LLC
3900 Stoneridge Ln, 
Dublin, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jennifer Woyach is a Hematologist and an Oncologist in Dublin, Ohio. Dr. Woyach has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Aspiration. Dr. Woyach is currently accepting new patients.

Her clinical research consists of co-authoring 218 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 1 clinical trial in the study of Waldenstrom Macroglobulinemia.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in OH
Hospital Affiliations
Ohio State University State Health System
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

OSU INTERNAL MEDICINE LLC
3900 Stoneridge Ln, Dublin, OH 43017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia
An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia
Enrollment Status: Recruiting
Publish Date: July 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: January 27, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Rituximab
Study Phase: Phase 1/Phase 2
Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study
Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Daratumumab, Ibrutinib
Study Phase: Phase 1
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)
Enrollment Status: Completed
Publish Date: December 15, 2025
Intervention Type: Biological, Other, Drug
Study Drugs: Lenalidomide, Anti-CD19 Monoclonal Antibody
Study Phase: Phase 2
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bendamustine, Ibrutinib, Rituximab
Study Phase: Phase 3
A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug, Other
Study Drugs: Selinexor, Ibrutinib
Study Phase: Phase 1
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients With CLL/SLL
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Other
A Phase I Study of Duvelisib in Combination With Nivolumab for Patients With Richter's Syndrome and Transformed Follicular Lymphoma
A Phase I Study of Duvelisib in Combination With Nivolumab for Patients With Richter's Syndrome and Transformed Follicular Lymphoma
Enrollment Status: Completed
Publish Date: May 02, 2024
Intervention Type: Drug, Biological
Study Drugs: Duvelisib, Nivolumab
Study Phase: Phase 1
Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In
Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In
Enrollment Status: Completed
Publish Date: December 26, 2023
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 1
A Phase 1, Open-label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease
A Phase 1, Open-label Study of SNX-5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease
Enrollment Status: Terminated
Publish Date: February 22, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label Study of SNX-5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase
A Phase 1, Open-label Study of SNX-5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase
Enrollment Status: Withdrawn
Publish Date: July 30, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 13 Less Clinical Trials

217 Total Publications

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2025
Similar Doctors
Kami J. Maddocks
Distinguished in Waldenstrom Macroglobulinemia
Dr. Kami J. Maddocks
Hematology
Distinguished in Waldenstrom Macroglobulinemia
Dr. Kami J. Maddocks
Hematology

Osu Internal Medicine LLC

410 W 10th Ave, Doan 110, 
Columbus, OH 
 (8.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kami Maddocks is a Hematologist in Columbus, Ohio. Dr. Maddocks is rated as an Elite provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Maddocks is currently accepting new patients.

Advanced in Waldenstrom Macroglobulinemia
Dr. Beth A. Christian
Hematology | Hematology Oncology
Advanced in Waldenstrom Macroglobulinemia
Dr. Beth A. Christian
Hematology | Hematology Oncology

Osu Internal Medicine LLC

3900 Stoneridge Ln, 
Dublin, OH 
 (0.1 miles away)
614-366-5001
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Beth Christian is a Hematologist and a Hematologist Oncology provider in Dublin, Ohio. Dr. Christian is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. Her top areas of expertise are Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma, and Bone Marrow Aspiration. Dr. Christian is currently accepting new patients.

Advanced in Waldenstrom Macroglobulinemia
Dr. Manish R. Sheth
Hematology Oncology | Hematology | Oncology
Advanced in Waldenstrom Macroglobulinemia
Dr. Manish R. Sheth
Hematology Oncology | Hematology | Oncology

Premier Health Specialists Inc

2300 Miami Valley Dr, Fl 4, 
Centerville, OH 
 (62.0 miles away)
937-276-8320
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Manish Sheth is a Hematologist Oncology specialist and a Hematologist in Centerville, Ohio. Dr. Sheth is rated as a Distinguished provider by MediFind in the treatment of Waldenstrom Macroglobulinemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Colorectal Cancer, Familial Colorectal Cancer, and Adenoid Cystic Carcinoma. Dr. Sheth is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Woyach's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile